Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Announcement & Circular
Stock Information
02186.HK
2.17 -0.03  (-1.36%)
Volume：31,935,000
05-29
2026
FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING TO BE HELD ON 26 JUNE 2026
Publisher：
05-29
2026
NOTICE OF ANNUAL GENERAL MEETING
Publisher：
05-29
2026
PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES AND RE-ELECTION OF RETIRING DIRECTORS INCLUDING INDEPENDENT NON-EXECUTIVE DIRECTOR WHO HAS SERVED MORE THAN ...
Publisher：
05-07
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Publisher：
04-29
2026
Environmental, Social and Governance Report 2025
Publisher：
04-29
2026
Annual Report 2025
Publisher：
04-20
2026
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE U.S. PK BRIDGING CLINICAL TRIAL OF THE GROUP'S INNOVATIVE DRUG LY03015 (VMAT2 INHIBITOR/SIGMA-1R AGONIST)
Publisher：
04-15
2026
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE CHINA PHASE II CLINICAL TRIAL OF THE GROUP'S INNOVATIVE DRUG LY03017 FOR TREATING ALZHEIMER'S DISEASE-RELATED PSYCHOSIS
Publisher：
04-08
2026
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE PHASE II CLINICAL TRIAL IN CHINA OF THE GROUP'S INNOVATIVE DRUG LY03020
Publisher：
04-08
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Publisher：
First
1
2
3
4
5
Last
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Stock Information
02186.HK
Volume：31,935,000
2.17
-0.03  (-1.36%)
Announcement & Circular
05-29
2026
FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING TO BE HELD ON 26 JUNE 2026
05-29
2026
NOTICE OF ANNUAL GENERAL MEETING
05-29
2026
PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES AND RE-ELECTION OF RETIRING DIRECTORS INCLUDING INDEPENDENT NON-EXECUTIVE DIRECTOR WHO HAS SERVED MORE THAN NINE YEARS ON THE BOARD AND RE-APPOINTMENT OF AUDITORS AND NOTICE OF ANNUAL GE
05-07
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
04-29
2026
Environmental, Social and Governance Report 2025
04-29
2026
Annual Report 2025
04-20
2026
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE U.S. PK BRIDGING CLINICAL TRIAL OF THE GROUP'S INNOVATIVE DRUG LY03015 (VMAT2 INHIBITOR/SIGMA-1R AGONIST)
04-15
2026
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE CHINA PHASE II CLINICAL TRIAL OF THE GROUP'S INNOVATIVE DRUG LY03017 FOR TREATING ALZHEIMER'S DISEASE-RELATED PSYCHOSIS
04-08
2026
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN THE PHASE II CLINICAL TRIAL IN CHINA OF THE GROUP'S INNOVATIVE DRUG LY03020
04-08
2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
First
1
2
3
4
5
Last